Table 1 Baseline clinicopathological characteristics of patients with APC
Characteristics | Training cohort (n = 59) | Validation cohort (n = 25) | P-value |
|---|---|---|---|
Age (median, SD) | 66 (9.5) | 70 (11.3) | 0.625 |
Gender | Â | Â | Â |
Male | 35 (59.3%) | 12 (48.0%) | 0.339 |
Female | 24 (40.7%) | 13 (52.0%) | Â |
ECOG PS | Â | Â | Â |
0–1 | 13 (22.0%) | 6 (24.0%) | 0.844 |
2 | 46 (78.0%) | 19 (76.0%) | Â |
Chemotherapy | Â | Â | Â |
Monotherapy | 27 (45.8%) | 10 (40.0%) | 0.627 |
Combination therapy | 32 (54.2%) | 15 (60.0%) | Â |
Effect | Â | Â | Â |
PR | 10 (16.9%) | 4 (16.0%) | 0.911 |
SD | 23 (39.0%) | 11 (44.0%) | Â |
PD | 26 (44.1%) | 10 (40.0%) | Â |
TNM stage | Â | Â | Â |
III | 10 (16.9%) | 7 (28.0%) | 0.249 |
IV | 49 (83.1%) | 18 (72.0%) | Â |
Primary tumor location | Â | Â | Â |
Head and neck | 31 (52.5%) | 18 (72.0%) | 0.098 |
Body and tail | 28 (47.5%) | 7 (28.0%) | Â |
CA19-9 (U/ml) | Â | Â | Â |
< 1000 | 40 (67.8%) | 18 (72.0%) | 0.703 |
≥ 1000 | 19 (32.2%) | 7 (28.0%) |  |